Navigation Links
Data published in PNAS show antibodies can be made 10 times more toxic to cancer cells

Engineering the "Fc" region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer therapies, according to research conducted at Xencor, which will be published in the March 14 print issue of the Proceedings of the National Academy of Sciences (PNAS).

Monoclonal antibodies have important advantages over chemotherapy and small molecule drug treatments for cancer, such as their specificity in targeting tumor cells and low toxicity. There are currently eight approved anticancer antibody products on the market today and many more are in development. Unfortunately, many marketed treatments lack the desired potency against tumor cells, providing only incremental improvements in therapeutic success, and many development-stage antibodies fail in clinical trials due to lack of demonstrated efficacy.

Scientists at Xencor, a biotherapeutics company developing protein and antibody therapeutics, said the changes it made to the antibody Fc regions increased antibody effector functions such as activation of immune cells for tumor lysis, called Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), by more than two orders of magnitude. Studies conducted in in vivo models demonstrated that these antibodies were greater than ten times more toxic to target cells. The enhanced antibodies also were able to kill tumor cells that are typically "invisible" to other antibodies because they express low levels of target antigen.

"While antibodies such as Genentech's Rituxan are well known for their role in the treatment of cancer, many other promising antibodies are sub-optimal for use as therapeutics. They just aren't powerful enough," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "The work we published in PNAS shows that specific changes to the Fc regions of antibodies have the potential to greatly improve the effectiveness of next-generation antibody therapeutics, and may mean that
'"/>

Source:Porter Novelli, Life Sciences


Page: 1 2

Related biology news :

1. Comprehensive biodefense text published
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
4. Combating anthrax: Results of study published this month as researchers look for a better vaccine
5. Genomic comparison of lactic acid bacteria published
6. The first tree genome is published: Poplar holds promise as renewable bioenergy resource
7. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
8. Horse antibodies against the bird flu virus H5N1 are effective as treatment in mice
9. Mice studies illustrate potential of chimp/human antibodies to protect against smallpox
10. GlycoFi announces the first production of antibodies with human glycosylation in yeast
11. Report calls for improved monoclonal antibodies against solid tumors
Post Your Comments:
(Date:4/15/2014)... Zero-emission hydrogen fuel cell systems soon could be powering ... at lower costs and with faster refueling times than ... Laboratories and Hawaii Hydrogen Carriers (HHC). , The goal ... storage system that can refuel at low pressure four ... a battery-powered forklift, giving hydrogen a competitive advantage over ...
(Date:4/15/2014)... New research published in the March/April 2014 ... of Nutrition shows whey protein, either as a ... a weight-loss or weight-maintenance diet, may provide men and ... meta-analysis included 14 randomized controlled trials with a total ... loss studies that used whey protein to replace calories ...
(Date:4/14/2014)... but if you,re over 24 years of age you,ve ... motor performance, according to a new Simon Fraser University ... student, associate professor Mark Blair, Thompson,s thesis supervisor, and ... deliver the news in a just-published PLOS ONE ... first social science experiments to rest on big data, ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
... at the U.S. Department of Energy's Brookhaven National Laboratory ... and database of the brain of a popular laboratory ... the world can now download these extremely accurate anatomical ... such as which parts of the brain are metabolically ...
... Americans found in volcanic rock in Mexico are either extremely ... evidence of human presence in the Western Hemisphere - or ... this week in Nature. , The study was conducted by ... California, Berkeley, as part of an investigative team of geologists ...
... fresh waters occurs worldwide but is largely unrecognized because ... fishery declines, according to an article in the December ... inland waters and their fish species should be of ... have received scant attention from conservation groups and the ...
Cached Biology News:Alleged 40,000-year-old human footprints in Mexico much, much older than thought 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 3Alleged 40,000-year-old human footprints in Mexico much, much older than thought 4Overfishing in inland waters reduces biodiversity and threatens health 2
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Reportlinker.com announces that a new market ... Sample Preparation and Library ... Kalorama Survey of Labs) ... and library preparation are important steps in ...
... 10 January 2011 Elsevier announced today ... Materials, Carbon Nanotubes and Nitrides, will occur on 4-8 ... conference discusses the significant improvements in material growth processes, ... past few years. The improvements have lead to the ...
... Pharma Inc., today announced that it has successfully completed ... enzyme replacement therapy being investigated in juveniles with hypophosphatasia ... were presented by Robert Heft, Ph.D., President and Chief ... Morgan Healthcare Conference in San Francisco. The ...
Cached Biology Technology:Reportlinker Adds Sample Preparation and Library Preparation for DNA Sequencers (Results of The Kalorama Survey of Labs) 2Reportlinker Adds Sample Preparation and Library Preparation for DNA Sequencers (Results of The Kalorama Survey of Labs) 3Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: